Continuous intra-arterial chemotherapy for downstaging locally advanced oral commissure carcinoma

Background The purpose of this study was to assess the usefulness, safety, and efficacy of intra‐arterial (IA) infusion chemotherapy for patients with locally advanced oral commissure cancer. Methods Twenty‐one patients with stages III and IV squamous cell carcinoma involving the mouth angle were re...

Full description

Saved in:
Bibliographic Details
Published in:Head & neck 2014-07, Vol.36 (7), p.1027-1033
Main Authors: Wu, Chih-Fung, Chang, Kao-Ping, Huang, Chih-Jen, Chen, Chun-Ming, Chen, Ching-Yi, Steve Lin, Chen-Lung
Format: Article
Language:English
Subjects:
Adult
Aged
Antimetabolites, Antineoplastic - administration & dosage
Antimetabolites, Antineoplastic - adverse effects
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - mortality
Carcinoma, Squamous Cell - pathology
Carotid Artery, Internal
chemotherapy
Disease-Free Survival
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Infusions, Intra-Arterial - methods
intra-arterial infusion
Lip Neoplasms - drug therapy
Lip Neoplasms - mortality
Lip Neoplasms - pathology
Male
methotrexate
Methotrexate - administration & dosage
Methotrexate - adverse effects
Middle Aged
Mouth Mucosa - pathology
oral commissure
Retrospective Studies
squamous cell carcinoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The purpose of this study was to assess the usefulness, safety, and efficacy of intra‐arterial (IA) infusion chemotherapy for patients with locally advanced oral commissure cancer. Methods Twenty‐one patients with stages III and IV squamous cell carcinoma involving the mouth angle were recruited. Methotrexate (MTX; 50 mg/day) was continuously infused into the external carotid artery for a mean period of 8 days, followed by weekly IA bolus of 25 mg MTX for a mean period of 10 weeks. Results Thirteen patients (62%) achieved a complete response (CR) and 7 patients (33%) had a partial response (PR). At a median follow‐up of 69 months, the estimated 1‐year, 3‐year, and 5‐year survival rates of the patients with CR versus PR were 100% versus 57%, 92% versus 43%, and 80% versus 43%, respectively. Conclusion Our data demonstrate that continuous IA chemotherapy could achieve a competitive acceptable survival rate and improved locoregional control of advanced oral commissure cancer. © 2013 Wiley Periodicals, Inc. Head Neck 36: 1027–1033, 2014
ISSN:1043-3074
1097-0347
DOI:10.1002/hed.23408